Member area login
You don't have or don't remember the password!
Click Here
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

EIC Assistant
Francesco Busardò

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada

Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Chiara Riva
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282


ISSN print: 0393 – 0564
ISSN digital: 0392- 7091

BC: Articoli scritti da B. Caruso

Determinazione delle immunoglobuline E specifiche
SIBioC Position statement about in vitro immunoglobulin E (IgE) testing
<p>The aim of this document is to contribute to increase the knowledge of the diagnostic significance and the clinical value of laboratory tests that are included in the in vitro category of allergy tests. In this context, the clinical benefits of the in vitro determination of specific immunoglobulins E (IgE) for complete extracts or single allergen molecules is to be strongly reaffirmed. This test is to be consider central in the diagnostic algorithm of allergic diseases compared to Skin Prick Test.</p>
Biochimica Clinica ; 42(1) 74-78
Documenti SIBioC - SIBioC Documents
Il ruolo di CA 15-3 nel monitoraggio della terapia nel carcinoma mammario metastatico
Role of CA15-3 to guide therapy in metastatic breast cancer
C. Cocco  |  B. Caruso  |  E. Fiorio  | 
<p>The National Academy of Clinical Biochemistry&nbsp;states that cancer antigen 15-3 (CA15-3) in combination with imaging and clinical examinations can be used for&nbsp;therapeutic monitoring in patients with advanced breast cancer. In a 62 year old patient with a 2 year history of&nbsp;invasive ductal breast carcinoma and bone metastasis, treated with an aromatase inhibitor, the imaging showed bone&nbsp;marrow infiltration and liver metastasis. The oncologist planned a close monitoring of the disease and the patient has&nbsp;been followed for two years by CA15-3 every month and imaging when necessary. It has been observed that the&nbsp;clinician modified the therapy on the basis of the CA15-3 values during two phases of apparent stability of the&nbsp;disease. This case report shows that the CA15-3 has contributed to a large extent to stop ineffective treatments and&nbsp;has effectively helped the clinician in selecting the most appropriate treatment options. However, it is to be noted that&nbsp;the monthly request of the marker is not appropriate.</p>
Biochimica Clinica ; 40(2) e08-e11
Casi clinici - Case report
Dabigatran e analisi di laboratorio
Dabigatran and laboratory tests
R. Facchinetti  |  B. Capizzi  |  B. Caruso  |  M. Negri  |  R. Suppi  |  G. Molon  |  G.C. Guidi  | 
<p>New oral anticoagulants (i.e., dabigatran, rivaroxaban, apixaban) are now&nbsp;available. In using these drugs, routine monitoring of laboratory coagulation tests is not recommended. In some&nbsp;clinical conditions, however, a laboratory evaluation of hemostatic balance may be useful. Tests suggested for&nbsp;laboratory monitoring of dabigatran treatment are thrombin time on undiluted (TT) or diluted (dTT) plasma and ecarin&nbsp;clotting time. On 30 patients taking dabigatran for non valvular atrial fibrillation, we assayed dabigatran levels by dTT,&nbsp;also performing prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen and TT. In patients&nbsp;taking dabigatran etexilate 110 mg bis in die and 150 mg bis in die, dTT mean results (10<sup>th</sup>-90<sup>th</sup> percentile) were 97&nbsp;(32-152) and 94 (33-189) &mu;g/L, respectively. In dTT range from 13 to 60 &mu;g/L and &gt;60 &mu;g/L, we obtained 27% and&nbsp;58% prolonged PT, 64% and 95% prolonged APTT, and 100% and 100% prolonged TT, respectively, showing that for&nbsp;dabigatran TT is a useful screening test.</p>
Biochimica Clinica ; 39(1) 041-047
Contributi scientifici - Scientific Papers
Osteoporosi maschile e anafilassi da imenotteri
Male osteoporosis and hymenoptera venom anaphylaxis
<p>Mastocytosis is one of the rare causes of unexplained&nbsp;osteoporosis, above all in males. On the other hand, a strict association between severe systemic reactions after&nbsp;hymenoptera sting and mastocytosis was recently demonstrated. Here we report a case of unexplained severe&nbsp;osteoporosis with multiple vertebral fractures in a 48 years old male, which also suffered an anaphylactic reaction after&nbsp;hymenoptera sting. Among laboratory tests performed to clarify the cause of osteoporosis, serum tryptase&nbsp;concentrations were determined. The value of tryptase was 43.6 &mu;g/L, four times higher than the upper reference limit.&nbsp;Skin did not show abnormalities; bone marrow vertebral biopsy was not valuable, but bone marrow aspirate from iliac&nbsp;crest demonstrated the presence of atypical mast cells expressing CD25; D816V mutation of KIT gene was also&nbsp;identified. These findings, in association with an increase of serum tryptase concentrations, fulfil all minor criteria&nbsp;requested for the diagnosis of systemic mastocytosis. Osteoporosis treatment with zolendronate and vitamin D&nbsp;supplementation was started, but later, for the persistence of bone pain, therapy with -interferon was added. This case&nbsp;confirms that an unexplained osteoporosis, especially if associated with hymenoptera sting systemic reaction, requires&nbsp;exclusion of a systemic mastocytosis.</p>
Biochimica Clinica ; 38(4) 347-349
Casi clinici - Case report
La mastocitosi sistemica: un approccio multidiscliplinare
Systemic mastocytosis: a muldisciplinary approach
<p>Systemic mastocytosis (SM) is a clonal disorder with complex manifestations determined by the proliferation and accumulation of mast cells in various organs (mainly in skin and bone marrow) and by the release of soluble mediators. Indolent SM is the more frequent variant of the disease, but its actual prevalence is unknown as the majority of patients suffering from SM are misdiagnosed, particularly when skin lesions are absent. Anaphylactic reactions to Hymenoptera (and less frequently to drugs or foods), idiopatic anaphylaxis, unexplained osteoporosis, or unexplained gastrointestinal symptoms are common manifestations of SM in absence of skin involvement. Therefore, the diagnosis and management of patients with SM require a multidisciplinary approach, which encompasses hematological, allergological, dermatological, rheumatological, and gastroenterological evaluations. A correct and timely diagnosis is required for: a) adequate counseling of patients and their physicians; b) beginning of symptomatic treatment (antimediator therapy); c) prevention of more severe manifestations of the disease (i.e., recurrent anaphylaxis, osteoporosis, bone fractures). In this paper, the epidemiology, classification, diagnostic tools, clinical manifestations, and therapy of SM are reviewed and a guidance on multidisciplinary approach to SM is provided.</p>
Biochimica Clinica ; 36(3) 158-170
Rassegna - Reviews
E' possibile utilizzare la determinazione della lipocalina associata alla gelatinasi dei neutrofili (NGAL) nella valutazione della nefrotossicità da bisfosfonati?
Biochimica Clinica ; 35(4) 331